GlassScriptPhysician profile
Devin Scott Reed
NPI 1427549591
$13,427.00
in general payments reported to CMS, 2019-2025
10 companies · $5,795 in 2025
The $5,795 reported for 2025 was more than what 98% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.63 · 2022: $141 · 2023: $1,310 · 2024: $6,170 · 2025: $5,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,167 · Food and Beverage: $6,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,167.09 |
| Food and Beverage | $6,107.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,078.17 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Medtronic, INC. | $4,672.80 | 2025 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Abbott Laboratories | $1,389.61 | 2024 | Eterna, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.52 | 2024 | Relistor |
| Pfizer INC. | $60.00 | 2023 | |
| Averitas Pharma INC. | $28.12 | 2023 | Qutenza |
| Nevro Corp. | $26.68 | 2024 | Senza |
| Si-Bone, INC. | $21.31 | 2025 | |
| Collegium Pharmaceutical, INC. | $17.16 | 2025 | Belbuca |
| Merck Sharp & Dohme LLC | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.